Corelight Technologies has built the world's first enclosed spherical positron production and capture system — consolidating synthesis, moderation, and containment into a single unified geometry. Against an equivalent open single-beam geometry, conventional capture is 0.00%. The Corelight Sphere achieves 13.39% — confirmed across 1.2 million simulated particles.
Every positron production system built before the Corelight Sphere used the same fundamental architecture — produce positrons in one place, transport them through a beamline, moderate them somewhere else, and attempt to trap them in a separate device. At every transition between stages, the majority of positrons are lost.
The Corelight Sphere eliminates every transition loss by doing everything simultaneously inside one enclosed spherical geometry. The result is a geometric capture efficiency that no separated-stage system can match — confirmed across 1.2 million simulated particles.
The simulation was challenged from every direction a rigorous peer reviewer would challenge it. Seed variation. Production cut sensitivity. Physics model dependence. Energy range. Port-by-port symmetry. Every dimension passed.
The Corelight Sphere hardware is identical across every application. What changes is the peripheral attachment. We license to qualified partners in each market — simultaneously, at premium rates, retaining ownership permanently.
PET imaging depends on short-lived radioisotopes — primarily Fluorine-18, with a 110-minute half-life — that must be produced, tested, and delivered within hours of use. The majority of hospitals depend entirely on regional cyclotron supply chains: expensive, geographically limiting, and fragile.
The Corelight Sphere enables on-site, on-demand isotope production at a fraction of the footprint and capital cost of existing cyclotron infrastructure. No external supply chain. No delivery window. No isotope waste from transit delays. Fresh dose when the patient arrives.
For rural and underserved hospitals currently without access to PET imaging, this is the first viable path to on-site nuclear medicine. For large academic medical centers, it eliminates the single largest operational vulnerability in their imaging program.
At sub-2nm process nodes, conventional optical and electron-beam inspection tools are physically limited to surface characterization. They cannot resolve atomic-scale open-volume defects — vacancy clusters, copper interconnect voids, hafnium oxide gate traps — buried within device layers. Foundries discover yield-critical defects only at final test, after weeks of fabrication and tens of millions in sunk processing cost.
Positron annihilation spectroscopy is the only technique capable of non-destructive, depth-profiled, atomic-scale defect characterization throughout the full device stack. Until now, it required reactor-based facilities with multi-week turnaround.
The Corelight Sphere delivers the first compact, on-site positron source capable of inline PAS at the pace of manufacturing. A 0.5% yield improvement at a leading-edge node is worth hundreds of millions annually to a major foundry.
The complete technical package is available to qualified institutional engineering teams and licensing partners. Access requires execution of a mutual confidentiality agreement prior to disclosure of any proprietary materials.
Complete the form below. Qualified contacts will receive a mutual confidentiality agreement for execution within 48 business hours. Data Room access is granted upon return of executed agreement.
Corelight Technologies was founded by Jacob Sporn in Boynton Beach, Florida. The core architectural insight was conceived in April 2025 — without institutional affiliation, without external funding, and with no prior art to reference. Every element of the invention was developed independently.
The simulation methodology has been reviewed at doctoral defense level by independent technical evaluators. Results confirmed across 1.2 million simulated particles with exact conservation on every run. Eight independently patentable IP elements. Patent application in progress.
All intellectual property is wholly owned — no institutional assignment, no co-inventor obligations, no encumbrances. Licensing freedom across all commercial verticals is complete.